CHF20,000 each for Clémedi and Nagi Bioscience
29.06.2018
These stage 2 Kickers offer a breakthrough for clinical microbiology and a worm-on-a-chip solution for the life sciences.
 |
 |
 |
|
Clemedi – Sebastian Dümcke & Prajwal Prajwal – medtech
Clémedi’s technology creates a highly efficient automated workflow for microbiology diagnostics, resulting in a faster diagnosis, more effective therapy, and reduction in consumption of antibiotics – thereby limiting the spread of antimicrobial resistance.
Nagi Bioscience – Matteo Cornaglia – life sciences
This EPFL spin-off introduces the first organism-on-chip technology, which combines the use of the tiny worm caenorhabditis elegans for in-vivo testing with a technological platform for fully automated in-vitro handling, culture and analysis. This innovation can boost efficiency in the pharmaceutical, cosmetic and chemical industries and reduce animal testing.
Clémedi’s technology creates a highly efficient automated workflow for microbiology diagnostics, resulting in a faster diagnosis, more effective therapy, and reduction in consumption of antibiotics – thereby limiting the spread of antimicrobial resistance.
Nagi Bioscience – Matteo Cornaglia – life sciences
This EPFL spin-off introduces the first organism-on-chip technology, which combines the use of the tiny worm caenorhabditis elegans for in-vivo testing with a technological platform for fully automated in-vitro handling, culture and analysis. This innovation can boost efficiency in the pharmaceutical, cosmetic and chemical industries and reduce animal testing.